Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuncell-LC in HCC Liver Transplant
NCT03983967Phase 2Completed
- Sponsor
- GC Cell
- Start
- Jan 2019
- Primary completion
- Sep 2021
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of immuncell-lc in hepatocellular carcinoma (HCC), sponsored by GC Cell. Primary endpoint: Maximum Tolerated Dose at 44 weeks. Started Jan 2019; status: completed.
02
Drugs
immuncell-lc
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03983967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03983967.